SML3662
Etrasimod arginine
≥98% (HPLC)
别名:
APD 334 L-Arginine, L-Arginine mono[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indol-3-yl]acetate, L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
![1,1,2-三甲基-1H-苯并[e]吲哚 ≥98.0% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/296/735/4c0b92e3-1a5f-4c32-8b5b-0b0997c15df4/640/4c0b92e3-1a5f-4c32-8b5b-0b0997c15df4.png)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear (Warmed)
储存温度
-10 to -25°C
SMILES字符串
N[C@@H](CCCNC(N)=N)C(O)=O.O=C(O)C[C@H]1CCC2=C1NC3=C2C=C(OCC4=CC=C(C5CCCC5)C(C(F)(F)F)=C4)C=C3
InChI key
GVPVVOSNDUAUKM-BPGOJFKZSA-N
生化/生理作用
Etrasimod arginine is an orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1). Also, it acts as a partial agonist of S1PR4,5. Etrasimod arginine induces reductions in lymphocyte counts in mice. It is acting as immunosuppressive agents.
Orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1)
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
Arianna Dal Buono et al.
Biomedicines, 10(7) (2022-07-28)
Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to induce endoscopic remission, reduce the
Hussien Al-Shamma et al.
The Journal of pharmacology and experimental therapeutics, 369(3), 311-317 (2019-03-16)
Lymphocyte trafficking out of secondary lymphoid organs is regulated by concentration gradient-dependent interactions between the membrane-derived lysophospholipid signaling molecule sphingosine 1-phosphate (S1P) and the G-protein-coupled receptor, S1P1 Etrasimod is a novel, next-generation, small-molecule, oral S1P receptor modulator in clinical development
Matej Zore et al.
Frontiers in microbiology, 13, 926170-926170 (2022-06-24)
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development. In this study, we screened a library of sphingosine-1-phosphate receptor (S1PR) modulators against
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门